Atezolizumab for the treatment of breast cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
   PubMed Web of Science ®Google Scholar
• Mathé G Active immunotherapy. In: Kleln G, Weinhouse S, Haddow A, editors. Adv. Cancer Res. [Internet]. Academic Press; 1971. p. 1–36. cited 2017 Sep 22. Available from:http://www.sciencedirect.com/science/article/pii/S0065230X08605175
   Google Scholar
• Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33:1889–1894.
   PubMed Web of Science ®Google Scholar
• Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. Jama. 2016;315:1600–1609.
   PubMed Web of Science ®Google Scholar
• Lipson EJ, Forde PM, Hammers H-J, et al. Antagonists of PD-1 and PD-L1 in cancer treatment. Semin Oncol. 2015;42:587–600.
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006–2017.
   PubMed Web of Science ®Google Scholar
• Savas P, Salgado R, Denkert C, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016;13:228–241.
   PubMed Web of Science ®Google Scholar
• Cimino-Mathews A, Thompson E, Taube JM, et al. PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum Pathol. 2016;47:52–63.
   PubMed Web of Science ®Google Scholar
• Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet Lond Engl. 2016;387:1837–1846.
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet Lond Engl. 2017;389:255–265.
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet Lond Engl. 2016;387:1909–1920.
   PubMed Web of Science ®Google Scholar
• Basile D, Garattini SK, Bonotto M, et al. Immunotherapy for colorectal cancer: where are we heading? Expert Opin Biol Ther. 2017;17:709–721.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 2006;6:715–727.
   PubMed Web of Science ®Google Scholar
• Teschendorff AE, Gomez S, Arenas A, et al. Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules. BMC Cancer. 2010;10:604.
   PubMed Web of Science ®Google Scholar
• Kristensen VN, Vaske CJ, Ursini-Siegel J, et al. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci U S A. 2012;109:2802–2807.
   PubMed Web of Science ®Google Scholar
• Seo AN, Lee HJ, Kim EJ, et al. Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer. 2013;109:2705–2713.
   PubMed Web of Science ®Google Scholar
• Mahmoud SMA, Paish EC, Powe DG, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29:1949–1955.
   PubMed Web of Science ®Google Scholar
• Liu S, Lachapelle J, Leung S, et al. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res BCR. 2012;14:R48.
   PubMed Web of Science ®Google Scholar
• Ali HR, Provenzano E, Dawson S-J, et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol Off J Eur Soc Med Oncol. 2014;25:1536–1543.
   PubMed Web of Science ®Google Scholar
• Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11:889–896.
   PubMed Web of Science ®Google Scholar
• Ohara M, Yamaguchi Y, Matsuura K, et al. Possible involvement of regulatory T cells in tumor onset and progression in primary breast cancer. Cancer Immunol Immunother CII. 2009;58:441–447.
   PubMed Web of Science ®Google Scholar
• Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24:5373–5380.
   PubMed Web of Science ®Google Scholar
• Wang Y, Waters J, Leung ML, et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature. 2014;512:155–160.
   PubMed Web of Science ®Google Scholar
• Mao Y, Qu Q, Chen X, et al. The prognostic value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis. PloS One. 2016;11:e0152500.
   PubMed Web of Science ®Google Scholar
• Ibrahim EM, Al-Foheidi ME, Al-Mansour MM, et al. The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis. Breast Cancer Res Treat. 2014;148:467–476.
   PubMed Web of Science ®Google Scholar
• Yu X, Zhang Z, Wang Z, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis. Clin Transl Oncol. 2016;18:497–506.
   PubMed Web of Science ®Google Scholar
• Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31:860–867.
   PubMed Web of Science ®Google Scholar
• Salgado R, Denkert C, Campbell C, et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial. JAMA Oncol. 2015;1:448–454.
   PubMed Web of Science ®Google Scholar
• Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol Off J Eur Soc Med Oncol. 2014;25:1544–1550.
   PubMed Web of Science ®Google Scholar
• Loi S, Dushyanthen S, Beavis PA, et al. RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors. Clin Cancer Res Off J Am Assoc Cancer Res. 2016;22:1499–1509.
   PubMed Web of Science ®Google Scholar
• Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19:40–50.
   PubMed Web of Science ®Google Scholar
• Salgado R, Loi S. Tumour infiltrating lymphocytes in breast cancer: increasing clinical relevance. Lancet Oncol. 2018;19:3–5.
   PubMed Web of Science ®Google Scholar
• LBA13; Loi S, P. Schmid, et al. Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): results from KEYNOTE-086. Annals of Oncology (2017) 28 (suppl_5): v605- v649.
   Google Scholar
• LBA14; Kok M, H.M. Horlings, K. van de Vijver, et al. Adaptive phase II randomized non-comparative trial of nivolumab after induction treatment in triple negative breast cancer: TONIC-trial. Annals of Oncology (2017) 28 (suppl_5): v605-v649
   Google Scholar
• Loi S, Giobbie-Hurder A, Gombos A, et al. Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive advanced breast cancer: results from the PANACEA study (IBCSG 45-13/BIG 4-13/KEYNOTE-014).  Cancer Res. 2018;78:GS2–GS06 – GS2–GS06
   Google Scholar
• Adams S, Diamond JR, Hamilton EP et al. Phase Ib trial of atezolizumab in combination with n, ab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). J. Clin. Oncol. 2016;34:1009–1009.
   Google Scholar
• Atezolizumab extends survival for breast cancer. Cancer Discov. 2017;7:OF10.
   Google Scholar
• Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol Off J Eur Soc Med Oncol. 2015;26:259–271.
   PubMed Web of Science ®Google Scholar
• Denkert C, Wienert S, Poterie A, et al. Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Mod Pathol Off J U S Can Acad Pathol Inc. 2016;29:1155–1164.
   PubMed Web of Science ®Google Scholar
• McDermott DF, Sosman JA, Sznol M, et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34:833–842.
   PubMed Web of Science ®Google Scholar
• Ali A, Krecko L, Leitzel K, et al. Circulating PD-L1 (programmed death-ligand 1) and outcomes in a HER2-positive metastatic breast cancer cohort treated with first-line trastuzumab. J Clin Oncol. 2017;35:1024.
   Web of Science ®Google Scholar
• Henze A-T, Mazzone M. The impact of hypoxia on tumor-associated macrophages. J Clin Invest. 2016;126:3672–3679.
   PubMed Web of Science ®Google Scholar
• Hendry SA, Farnsworth RH, Solomon B, et al. The role of the tumor vasculature in the host immune response: implications for therapeutic strategies targeting the tumor microenvironment. Front Immunol. 2016;7:621.
   PubMed Web of Science ®Google Scholar
• Kandalaft LE, Motz GT, Busch J, et al. Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin. Curr Top Microbiol Immunol. 2011;344:129–148.
   PubMed Web of Science ®Google Scholar
• Voron T, Colussi O, Marcheteau E, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. 2015;212:139–148.
   PubMed Web of Science ®Google Scholar
• Santini FC, Rudin CM. Atezolizumab for the treatment of non-small cell lung cancer. Expert Rev Clin Pharmacol. 2017;10:935–945.
   PubMed Web of Science ®Google Scholar
• Stroh M, Winter H, Marchand M, et al. Clinical pharmacokinetics and pharmacodynamics of atezolizumab in metastatic urothelial carcinoma. Clin Pharmacol Ther. 2017;102:305–312.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Soria J-C, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563–567.
   PubMed Web of Science ®Google Scholar
• Emens LA, Braiteh FS, Cassier P, et al. Abstract PD1-6: inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer. Cancer Res. 2015;75:PD1–PD6 – PD1–PD6.
   Web of Science ®Google Scholar
• Schmid P, Cruz C, Braiteh FS, et al. Abstract 2986: Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses. Cancer Res. 2017;77:2986–2986.
   Google Scholar
• Dirix LY, Takacs I, Nikolinakos P, et al. Abstract S1-04: avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase Ib JAVELIN solid tumor trial. Cancer Res. 2016;76:S1–S04 – S1–S04.
   Web of Science ®Google Scholar
• Nanda R, Specht J, Dees C, et al. Abstract P6-10-03: KEYNOTE-012: long-lasting responses in a phase Ib study of pembrolizumab for metastatic triple-negative breast cancer (mTNBC). Cancer Res. 2017;77:P6–P10 – 03–P6 – 10–03.
   Web of Science ®Google Scholar
• Nanda R, Chow LQM, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34:2460–2467.
   PubMed Web of Science ®Google Scholar
• Adams S, Loi S, Toppmeyer D, et al. Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): preliminary data from KEYNOTE-086 cohort B. J Clin Oncol. 2017;35:1088.
   Google Scholar
• Tolaney S,Kalinsky K, Kaklamani V, et al. Abstract PD6-13: Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer.  Cancer Res. 2018;78:PD6–PD13 - PD6–PD13.
   Google Scholar
• Nishijima TF, Shachar SS, Nyrop KA, et al. Safety and tolerability of PD-1/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis. The Oncologist. 2017;22:470–479.
   PubMed Web of Science ®Google Scholar
• Weinstock C, Khozin S, Suzman D, et al. U.S. Food and Drug Administration approval summary: atezolizumab for metastatic non-small cell lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23:4534–4539.
   PubMed Web of Science ®Google Scholar
• Peters S, Gettinger S, Johnson ML, et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH). J Clin Oncol Off J Am Soc Clin Oncol. 2017;35:2781–2789.
   PubMed Web of Science ®Google Scholar
• Inman BA, Longo TA, Ramalingam S, et al. Atezolizumab: a PD-L1-blocking antibody for bladder cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23:1886–1890.
   PubMed Web of Science ®Google Scholar